View in EDS

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Saved in:
Bibliographic Details
Title: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Authors: Modi S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. modis@mskcc.org., Jacot W; Medical Oncology Department, Institut du Cancer de Montpellier, Université de Montpellier, INSERM U1194, Montpellier, France., Iwata H; Nagoya City University, Nagoya, Japan., Park YH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Vidal Losada M; Department of Medical Oncology, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Li W; First Hospital of Jilin University, Changchun, China., Tsurutani J; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan., Ueno NT; Translational and Clinical Research Program, University of Hawai'i Cancer Center, Honolulu, HI, USA., Zaman K; Department of Oncology, Lausanne University Hospital CHUV, Lausanne, Switzerland., Prat A; Clinic Barcelona Comprehensive Cancer Center, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Papazisis K; Euromedica General Clinic, Thessaloniki, Greece., Rugo HS; Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Yamashita T; Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, Japan., Harbeck N; Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., De Laurentiis M; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Pierga JY; Department of Medical Oncology, Institut Curie, Paris and Université Paris Cité, Paris, France., Wang X; Zhejiang Cancer Hospital, Hangzhou, China., Gombos A; Medical Oncology Department, Institut Jules Bordet, Brussels, Belgium., Tokunaga E; Department of Breast Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan., Orbegoso Aguilar C; Global Oncology R&D, Daiichi Sankyo France SAS, Rueil-Malmaison, France., Yung L; Clinical Development, Daiichi Sankyo Inc., Basking Ridge, NJ, USA., Xiao F; Biostatistics, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA., Cheng Y; Clinical Safety and Pharmacovigilance, Daiichi Sankyo Inc., Basking Ridge, NJ, USA., Cameron D; Edinburgh University Cancer Centre, University of Edinburgh, Edinburgh, UK.
Source: Nature medicine [Nat Med] 2025 Dec; Vol. 31 (12), pp. 4205-4213. Date of Electronic Publication: 2025 Oct 08.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41062831
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Modi+S%22">Modi S</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. modis@mskcc.org.<br /><searchLink fieldCode="AU" term="%22Jacot+W%22">Jacot W</searchLink>; Medical Oncology Department, Institut du Cancer de Montpellier, Université de Montpellier, INSERM U1194, Montpellier, France.<br /><searchLink fieldCode="AU" term="%22Iwata+H%22">Iwata H</searchLink>; Nagoya City University, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Park+YH%22">Park YH</searchLink>; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Vidal+Losada+M%22">Vidal Losada M</searchLink>; Department of Medical Oncology, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Li+W%22">Li W</searchLink>; First Hospital of Jilin University, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Tsurutani+J%22">Tsurutani J</searchLink>; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Ueno+NT%22">Ueno NT</searchLink>; Translational and Clinical Research Program, University of Hawai'i Cancer Center, Honolulu, HI, USA.<br /><searchLink fieldCode="AU" term="%22Zaman+K%22">Zaman K</searchLink>; Department of Oncology, Lausanne University Hospital CHUV, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Prat+A%22">Prat A</searchLink>; Clinic Barcelona Comprehensive Cancer Center, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Papazisis+K%22">Papazisis K</searchLink>; Euromedica General Clinic, Thessaloniki, Greece.<br /><searchLink fieldCode="AU" term="%22Rugo+HS%22">Rugo HS</searchLink>; Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Yamashita+T%22">Yamashita T</searchLink>; Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, Japan.<br /><searchLink fieldCode="AU" term="%22Harbeck+N%22">Harbeck N</searchLink>; Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Im+SA%22">Im SA</searchLink>; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22De+Laurentiis+M%22">De Laurentiis M</searchLink>; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.<br /><searchLink fieldCode="AU" term="%22Pierga+JY%22">Pierga JY</searchLink>; Department of Medical Oncology, Institut Curie, Paris and Université Paris Cité, Paris, France.<br /><searchLink fieldCode="AU" term="%22Wang+X%22">Wang X</searchLink>; Zhejiang Cancer Hospital, Hangzhou, China.<br /><searchLink fieldCode="AU" term="%22Gombos+A%22">Gombos A</searchLink>; Medical Oncology Department, Institut Jules Bordet, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Tokunaga+E%22">Tokunaga E</searchLink>; Department of Breast Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Orbegoso+Aguilar+C%22">Orbegoso Aguilar C</searchLink>; Global Oncology R&D, Daiichi Sankyo France SAS, Rueil-Malmaison, France.<br /><searchLink fieldCode="AU" term="%22Yung+L%22">Yung L</searchLink>; Clinical Development, Daiichi Sankyo Inc., Basking Ridge, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Xiao+F%22">Xiao F</searchLink>; Biostatistics, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Cheng+Y%22">Cheng Y</searchLink>; Clinical Safety and Pharmacovigilance, Daiichi Sankyo Inc., Basking Ridge, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Cameron+D%22">Cameron D</searchLink>; Edinburgh University Cancer Centre, University of Edinburgh, Edinburgh, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2025 Dec; Vol. 31 (12), pp. 4205-4213. <i>Date of Electronic Publication: </i>2025 Oct 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41062831
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-025-03981-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4205
    Titles:
      – TitleFull: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Modi S
      – PersonEntity:
          Name:
            NameFull: Jacot W
      – PersonEntity:
          Name:
            NameFull: Iwata H
      – PersonEntity:
          Name:
            NameFull: Park YH
      – PersonEntity:
          Name:
            NameFull: Vidal Losada M
      – PersonEntity:
          Name:
            NameFull: Li W
      – PersonEntity:
          Name:
            NameFull: Tsurutani J
      – PersonEntity:
          Name:
            NameFull: Ueno NT
      – PersonEntity:
          Name:
            NameFull: Zaman K
      – PersonEntity:
          Name:
            NameFull: Prat A
      – PersonEntity:
          Name:
            NameFull: Papazisis K
      – PersonEntity:
          Name:
            NameFull: Rugo HS
      – PersonEntity:
          Name:
            NameFull: Yamashita T
      – PersonEntity:
          Name:
            NameFull: Harbeck N
      – PersonEntity:
          Name:
            NameFull: Im SA
      – PersonEntity:
          Name:
            NameFull: De Laurentiis M
      – PersonEntity:
          Name:
            NameFull: Pierga JY
      – PersonEntity:
          Name:
            NameFull: Wang X
      – PersonEntity:
          Name:
            NameFull: Gombos A
      – PersonEntity:
          Name:
            NameFull: Tokunaga E
      – PersonEntity:
          Name:
            NameFull: Orbegoso Aguilar C
      – PersonEntity:
          Name:
            NameFull: Yung L
      – PersonEntity:
          Name:
            NameFull: Xiao F
      – PersonEntity:
          Name:
            NameFull: Cheng Y
      – PersonEntity:
          Name:
            NameFull: Cameron D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1